The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells
Seminars in Immunopathology · 2025-12 · 47 (1)
DOI: 10.1007/s00281-025-01047-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, online erschienen am 03.04.2025. Verfasst von Julianna Novák und 9 weiteren Autor:innen. Beteiligte Einrichtung: Signal Transduction and Functional Genomics Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budap…. Hauptthemen laut MEDLINE: Galectin 1, Neoplasms, Apoptosis, T-Lymphocytes. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HUN-REN Research Centre for Natural Sciences.
Abstract (Originalsprache)
Galectin-1 (Gal-1), a member of the β-galactoside-binding soluble lectin family, is a double-edged sword in immunity. On one hand, it plays a crucial role in regulating diverse immune cell functions, including the apoptosis of activated T cells. These processes are key in resolving inflammation and preventing autoimmune diseases. On the other hand, Gal-1 has significant implications in cancer, where tumor cells and the tumor microenvironment (TME) (e.g., tumor-associated fibroblasts, myeloid-derived suppressor cells) secrete Gal-1 to evade immune surveillance and promote cancer cell growth. Within the TME, Gal-1 enhances the differentiation of tolerogenic dendritic cells, induces the apoptosis of effector T cells, and enhances the proliferation of regulatory T cells, collectively facilitating tumor immune escape. Therefore, targeting Gal-1 holds the potential to boost anti-tumor immunity and improve the efficacy of cancer immunotherapy. This review provides insights into the intricate role of Gal-1 in immune cell regulation, with an emphasis on T cells, and elucidates how tumors exploit Gal-1 for immune evasion and growth. Furthermore, we discuss the potential of Gal-1 as a therapeutic target to augment current immunotherapies across various cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Signal Transduction and Functional Genomics Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, 1117, Hungary.
- Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Budapest, 1117, Hungary.
- Systems Biology of Reproduction Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, 1117, Hungary.
- Károly Rácz Conservative Medicine Division, Doctoral College, Semmelweis University, Budapest, 1091, Hungary.
- Department of Obstetrics and Gynecology, Semmelweis University, Budapest, 1088, Hungary.
- Department of Molecular Biology, Semmelweis University, Budapest, 1094, Hungary.
Förderung
- HUN-REN Research Centre for Natural Sciences
Zitieren
APA
Novák, J., Takács, T., Tilajka, Á., László, L., Oravecz, O., Farkas, E., Than, N. G., Buday, L., Balogh, A., & Vas, V. (2025). The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells. Seminars in Immunopathology, 47(1). https://doi.org/10.1007/s00281-025-01047-8
Vancouver
Novák J, Takács T, Tilajka Á, László L, Oravecz O, Farkas E, et al. The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells. Seminars in Immunopathology. 2025;47(1). doi:10.1007/s00281-025-01047-8
BibTeX
@article{Novk2025,
author = {Novák, Julianna and Takács, Tamás and Tilajka, Álmos and László, Loretta and Oravecz, Orsolya and Farkas, Emese and Than, Nándor Gábor and Buday, László and Balogh, Andrea and Vas, Virág},
title = {The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells},
journal = {Seminars in Immunopathology},
year = {2025},
volume = {47},
number = {1},
doi = {10.1007/s00281-025-01047-8}
}
EUVIMED